Leading Pharmaceutical Manufacturer Selects Skura SFX closed loop marketing software to Reach its Goals for Sales and Marketing

Leading Pharmaceutical Manufacturer Selects Skura SFX closed loop marketing software to Reach its Goals for Sales and Marketing Excellence

A top 10 global healthcare company devoted to discovering new medicines, new technologies and new ways to manage health is deploying the Skura SFXTM Suite to address the challenges it faces in today's sales and marketing environment.

Oakville, Ontario, May 18th, 2009:  Skura Corporation, the leader in closed loop marketing solutions in the Life Sciences Industry, is proud to announce that it has been awarded a critically important project to dramatically improve sales & marketing effectiveness.

After an exhaustive review of all vendors, the decision to select SFXTM for closed loop marketing was based on three simple but critical criteria: to improve sales effectiveness, create more impactful marketing campaigns, and deliver more compelling messages to physicians.

Jeff Wessinger, President of Skura Corporation, said, "Skura was chosen because it could clearly demonstrate that SFX is an innovative next generation solution that combines the most advanced Closed Loop Marketing feature set with the lowest total cost of ownership"  "Our unique ability to leverage existing CRM capabilities, and seamlessly publish and track existing creative materials, was key to winning this deal."

    
About Skura: 

Founded in 1996, Skura has grown into an international company with satisfied customers around the globe. Headquartered in Oakville, Ontario, Skura also has offices in the US and Europe.

Skura clients have benefited from our unique value proposition as a provider of Closed-Loop Marketing (CLM) solutions in the Life Sciences Industry.  As a recognized leader of software products and services, like the SFXTM Suite  Skura continues to earn an envied reputation within this industry as a recognized leader of innovative and award winning sales and marketing solutions.

For additional information, call 1.866.722.2040, or visit www.Skura.com

Suggested Articles

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company.

The RV144 HIV vaccine regimen containing clades B and E inserts produced strong immune responses in South Africa, where clade C dominates.